Samrat Pharmachem Ltd Q1 FY2022-23 profit jumps to Rs. 9.36 crores

SAMRAT PHARMACHEM LTD. has reported Standalone financial results for the period ended June 30, 2022.

Financial Results (Q1 FY2023) - QoQ Comparison

The company has reported total income of Rs. 86.5321 crores during the period ended June 30, 2022 as compared to Rs. 60.2439 crores during the period ended March 31, 2022.

The company has posted net profit / (loss) of Rs. 9.3665 crores for the period ended June 30, 2022 as against net profit / (loss) of Rs. 6.9947 crores for the period ended March 31, 2022.

The company has reported EPS of Rs. 30.32 for the period ended June 30, 2022 as compared to Rs. 22.64 for the period ended March 31, 2022.

Financials	Q1 FY2023	Q4 FY2022	% Change
Total Income	₹ 86.5321 crs	₹60.2439 crs	43.64%
Net Profit	₹9.3665 crs	₹6.9947 crs	33.91%
EPS	₹30.32	₹22.64	33.92%

Financial Results (Q1 FY2023) - YoY Comparison

The company has reported total income of Rs. 86.5321 crores during the period ended June 30, 2022 as compared to Rs.47.3918 crores during the period ended June 30, 2021.

The company has posted net profit / (loss) of Rs.9.3665 crores for the period ended June 30, 2022 as against net profit / (loss) of Rs.0.9535 crores for the period ended June 30, 2021.

The company has reported EPS of Rs.30.32 for the period ended June 30, 2022 as compared to Rs.3.09 for the period ended June 30, 2021.

Financials	Q1 FY2023	Q1 FY2022	% Change
Total Income	₹ 86.5321 crs	₹47.3918 crs	82.59%
Net Profit	₹9.3665 crs	₹0.9535 crs	882.33%
EPS	₹30.32	₹3.09	881.23%

Shares of SAMRAT PHARMACHEM LTD. was last trading in BSE at Rs. 495.30 as compared to the previous close of Rs. 477.25. The total number of shares traded during the day was 11426 in over 297 trades.

The stock hit an intraday high of Rs. 508.80 and intraday low of 475.50. The net turnover during the day was Rs. 5658158.00.

Source : Equity Bulls

Keywords

SamratPharmachem Q1FY23 ResultUpdate